Wells Fargo’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-4,492
| Closed | -$18K | – | 7237 |
|
|
2025
Q2 | $18K | Sell |
4,492
-28,531
| -86% | -$70.7K | ﹤0.01% | 5810 |
|
|
2025
Q1 | $30.1K | Buy |
33,023
+1,451
| +5% | +$2.01K | ﹤0.01% | 5569 |
|
|
2024
Q4 | $87.5K | Buy |
31,572
+7,038
| +29% | +$26.8K | ﹤0.01% | 5270 |
|
|
2024
Q3 | $128K | Buy |
24,534
+1,821
| +8% | +$9.45K | ﹤0.01% | 4873 |
|
|
2024
Q2 | $101K | Buy |
22,713
+5,855
| +35% | +$28.4K | ﹤0.01% | 4935 |
|
|
2024
Q1 | $129K | Buy |
16,858
+2,164
| +15% | +$11.9K | ﹤0.01% | 4745 |
|
|
2023
Q4 | $62.6K | Buy |
14,694
+6,253
| +74% | +$22.2K | ﹤0.01% | 5185 |
|
|
2023
Q3 | $35.5K | Sell |
8,441
-4,399
| -34% | -$22.4K | ﹤0.01% | 5353 |
|
|
2023
Q2 | $71.5K | Buy |
12,840
+12,675
| +7,682% | +$74.9K | ﹤0.01% | 5236 |
|
|
2023
Q1 | $945 | Buy |
165
+3
| +2% | +$8 | ﹤0.01% | 6398 |
|
|
2022
Q4 | $170 | Buy |
162
+5
| +3% | +$9 | ﹤0.01% | 6670 |
|
|
2022
Q3 | $0 | Sell |
157
-20
| -11% | -$72 | ﹤0.01% | 6977 |
|
|
2022
Q2 | $1K | Sell |
177
-2,778
| -94% | -$12.1K | ﹤0.01% | 6527 |
|
|
2022
Q1 | $12K | Sell |
2,955
-5,028
| -63% | -$29.6K | ﹤0.01% | 6204 |
|
|
2021
Q4 | $54K | Buy |
7,983
+7,935
| +16,531% | +$68.5K | ﹤0.01% | 5937 |
|
|
2021
Q3 | $1K | Hold |
48
| – | – | ﹤0.01% | 6722 |
|
|
2021
Q2 | $1K | Sell |
48
-1,655
| -97% | -$28.8K | ﹤0.01% | 6677 |
|
|
2021
Q1 | $34K | Sell |
1,703
-7,993
| -82% | -$176K | ﹤0.01% | 5990 |
|
|
2020
Q4 | $200K | Buy |
9,696
+3,583
| +59% | +$85.4K | ﹤0.01% | 5088 |
|
|
2020
Q3 | $161K | Buy |
+6,113
| New | +$152K | ﹤0.01% | 5067 |
|
Wells Fargo's INZY Position: Q3 2025 in Review
Wells Fargo sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 4,492 shares — an estimated $18K sold.
Wells Fargo first reported a position in INZY in Q3 2020 and held it in 20 quarters. The position peaked at $200K in Q4 2020. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Wells Fargo reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Wells Fargo sold 4,492 Inozyme Pharma shares in Q3 2025, an estimated $18K.
- Wells Fargo first reported a position in Inozyme Pharma in Q3 2020 and held it in 20 quarters.
- Wells Fargo's Inozyme Pharma position peaked at $200K in Q4 2020.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Wells Fargo's 13F filing for Q3 2025, filed 13 Nov 2025.